Valuation
Pharmaceutical PreparationsLive · Yahoo FinancePrice
$78.82
52-Week Range
Decision Context
Scores are balanced across the six engines. No single dimension dominates — this is consistent with a stable, mid-tier quality business.
Based on filing period ending Mar 2026
FisclearScore is a quantitative model using public financial data and sector median benchmarks (refreshed monthly). Not financial advice. Always conduct independent due diligence.
Macro Context
Fed Funds Rate
3.64%
Accommodative
10-Year Treasury
4.32%
2026-04-01
Unemployment
4.3%
Near full employment
CPI Index
330.3
2026-03-01
M2 Money Supply
$22.7T
2026-03-01
The Federal Funds rate stands at 3.64% — a moderately elevated rate environment that raises borrowing costs across the economy; 10-year Treasury yields are at 4.32%, setting the benchmark for long-term corporate borrowing; Unemployment stands at 4.3%; Industrial production index is at 101.8; M2 money supply is $22.7T; CPI index stands at 330.3.
SWOT Analysis — ZTS
Inflationary BoomStrengths
EPS (Diluted): $6.02 (+10.1% YoY) — Earnings per share rose 10% — each share earned more.
Total Assets: $15.5B (+8.6% YoY) — Total assets grew 9% — the company's resource base expanded.
Net Income: $2.7B (+7.5% YoY) — Profit grew 8% — the company kept more of each dollar earned.
Weaknesses
Operating Cash Flow: $2.9B (-1.7% YoY) — Operating cash flow fell 2% but remained positive.
Opportunities
Revenue: $9.5B (+2.3% YoY) — Revenue grew 2% — the company sold more goods or services than the prior year.
Threats
Total liabilities represent 78% of total assets — elevated leverage that amplifies both gains and losses.
Financial Charts
Revenue vs Net Income
Margin Trend
Operating Cash Flow
Year-over-Year Changes
EPS (Diluted)
$6.02
was $5.47
Earnings per share rose 10% — each share earned more.
Total Assets
$15.5B
was $14.2B
Total assets grew 9% — the company's resource base expanded.
Net Income
$2.7B
was $2.5B
Profit grew 8% — the company kept more of each dollar earned.
Revenue
$9.5B
was $9.3B
Revenue grew 2% — the company sold more goods or services than the prior year.
Operating Cash Flow
$2.9B
was $3.0B
Operating cash flow fell 2% but remained positive.
Risk Flags
0 high · 1 medium · 0 low- ◈ Medium
Total liabilities represent 78% of total assets — elevated leverage that amplifies both gains and losses.
Price History
Technical Signals
Daily closes · 1-year dataLatest News
via FinnhubGet the weekly digest
5 company reports + macro context every week, free. No spam.
- Unlimited goal simulations
- 5 free company report summaries per day
- Weekly financial insights newsletter
External Links
Trade ZTS
Links open broker research pages. Not an endorsement or recommendation.
Research Zoetis Inc.
Data sourced from SEC EDGAR, FRED (Federal Reserve Economic Data), and Yahoo Finance. For informational purposes only. Not financial advice.